<DOC>
	<DOCNO>NCT01391013</DOCNO>
	<brief_summary>The purpose study compare change brachial artery flow mediate vasodilatation use Darunavir/Ritonavir ( DRV/r ) 800/100 mg daily monotherapy ( use single medication ) versus triple combination therapy contain 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) DRV/r Human immunodeficiency virus-1 ( HIV-1 ) infect participant .</brief_summary>
	<brief_title>A Study Compare Brachial Artery Reactivity Cardiovascular Risk Treatment Simplification Darunavir/Ritonavir ( DRV/r ) 800/100 mg Versus Triple Combination Therapy Containing DRV/r HIV-1 Infected Patients</brief_title>
	<detailed_description>This Phase II , randomize ( study medication assign chance ) , open-label ( people know identity intervention ) , control , single centre study . The study consist 3 phase include , screen phase ( 4 week administration study medication ) , treatment phase ( 48 week ) , follow-up phase ( 4 week ) . In treatment phase , HIV-infected participant change first-line treatment highly active antiretroviral therapy ( HAART ) least 8 week document evidence HIV- ribonucleic acid ( RNA ) measurement virologically suppress ( HIV-RNA le 50 copies/mL ) least 24 week prior screen , randomly assign equally two treatment arm : triple combination therapy arm ( DRV/r 800/100 mg daily plus 2 NRTIs ) monotherapy arm ( DRV/r 800/100 mg daily ) . Participants triple combination arm already 2 NRTIs prior randomization may remain switch baseline , participant monotherapy arm discontinue HAART baseline start DRV/r 800/100 mg daily . Safety evaluation include assessment adverse event , significant vital sign , significant laboratory test . The total duration study 56 week .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Human immunodeficiency virus1 ( HIV1 ) infect participant firstline treatment highly active antiretroviral therapy ( HAART ) ( combination 2 3 nucleoside reverse transcriptase inhibitor [ NRTIs ] least 1 additional antiretroviral [ ARV ] nonnucleoside reverse transcriptase inhibitor [ NNRTI ] and/or protease inhibitor [ PI ] class ) least 24 week , provide ARV combination least 8 week screen Participants ' preference convenient regimen and/or current history toxicity actual regimen Plasma HIV1 ribonucleic acid ( RNA ) less 50 cp/ml least 24 week screening , single viral blip 50 copies/mL allow Cluster differentiation 4 ( CD4 ) count 100/mm3 start HAART 200/mm3 screen Healthy basis physical examination , medical history , vital sign , clinical laboratory test , 12lead electrocardiogram perform screen Agrees protocoldefined use effective contraception Postmenopausal , surgically sterile , abstinent female participant History coronary heart disease , uncontrolled hypertension , peripheral vascular disease cerebrovascular disease History virological failure highly active antiretroviral therapy , plasma HIV1 ribonucleic acid 500 copies/mL initial full virological suppression ARV therapy PI mutation Participants significantly hepatic liver insufficiency diagnose acute viral hepatitis active clinically significant disease acquire immune deficiency syndrome ( AIDS ) define illness screen Current significant tobacco use , active drug alcohol use dependence Use lipidlowering drug within 4 week prior study entry use testosterone , anabolic steroid , oral contraceptive hormonal replacement within 12 week prior study entry previous current use darunavir Use systemic glucocorticoid , longacting inhaled steroid ( inhaled via mouth nose ) , immunomodulators within 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Human immunodeficiency virus 1</keyword>
	<keyword>Acquired immunodeficiency syndrome</keyword>
	<keyword>Immunologic deficiency syndrome</keyword>
	<keyword>Darunavir/ritonavir</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Nucleoside reverse transcriptase inhibitor ( NRTIs )</keyword>
	<keyword>Prezista</keyword>
</DOC>